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System immunology-based identiﬁcation of blood
transcriptional modules correlating to antibody responses in
sheep
Roman Othmar Braun 1,2,3, Livia Brunner4, Kurt Wyler5, Gaël Auray1,3, Obdulio García-Nicolás1,3, Sylvie Python1,3, Beatrice Zumkehr1,
Véronique Gaschen6, Michael Hubert Stoffel6, Nicolas Collin4, Christophe Barnier-Quer4, Rémy Bruggmann5 and Artur Summerﬁeld1,3
Inactivated vaccines lack immunogenicity and therefore require potent adjuvants. To understand the in vivo effects of adjuvants,
we used a system immunology-based analysis of ovine blood transcriptional modules (BTMs) to dissect innate immune responses
relating to either antibody or haptoglobin levels. Using inactivated foot-and-mouth disease virus as an antigen, we compared non-
adjuvanted to liposomal-formulated vaccines complemented or not with TLR4 and TLR7 ligands. Early after vaccination, BTM
relating to myeloid cells, innate immune responses, dendritic cells, and antigen presentation correlated positively, whereas BTM
relating to T and natural killer cells, as well as cell cycle correlated negatively with antibody responses. Interestingly, similar BTM also
correlated with haptoglobin, but in a reversed manner, indicating that acute systemic inﬂammation is not beneﬁcial for early
antibody responses. Analysis of vaccine-dependent BTM modulation showed that liposomal formulations induced similar responses
to those correlating to antibody levels. Surprisingly, the addition of the TLR ligands appeared to reduce early immunological
perturbations and mediated anti-inﬂammatory effects, despite promoting antibody responses. When pre-vaccination BTM were
analyzed, we found that high vaccine responders expressed higher levels of many BTM relating to cell cycle, antigen-presenting
cells, and innate responses as compared with low responders. In conclusion, we have transferred human BTM to sheep and
identiﬁed early vaccine-induced responses associated with antibody levels or unwanted inﬂammation in a heterogeneous and
small group of animals. Such readouts are applicable to other veterinary species and very useful to identify efﬁcient vaccine
adjuvants, their mechanism of action, and factors related to low responders.
npj Vaccines  (2018) 3:41 ; doi:10.1038/s41541-018-0078-0
INTRODUCTION
In the past, vaccines were developed empirically requiring many
animal studies with a long-term follow-up to assess vaccine
efﬁcacy. Furthermore, although the mechanisms of many vaccine
adjuvants at the molecular and cellular level are clear, in vivo
protection is much more complex and still difﬁcult to understand
and predict. Systems immunology offers powerful approaches
towards dissecting the early innate immune response relating to
potent adaptive immune responses in human.1–3 This enabled to
identify genes expressed in peripheral blood leukocytes within the
ﬁrst days after vaccination, which correlated to CD8 T-cell or
antibody responses.2,3 Nevertheless, a main problem with this
relatively simple approach was the high heterogeneity of
individual responders and the difﬁculty to understand immuno-
logical processes from individual gene information. For these
reasons, a much more powerful analysis of transcriptomic data
was developed by identifying gene sets such as blood transcrip-
tional modules (BTMs) through large-scale data integration.1,4 To
this end, Li et al.1 established human blood transcriptomes from
540 data series containing over 32,000 samples obtained from
many disease-related studies to identify master networks of genes
co-regulated and interacting in cells of the immune system during
many physiological and pathological conditions. Certain BTM were
demonstrated to correlate with adaptive immune responses in a
vaccine type-speciﬁc manner enabling conclusions on immuno-
logical processes associated with desired vaccine responses.1
For foot-and-mouth disease (FMD), a devastating viral infection
affecting cloven-hooved animals, traditional vaccine approaches
are based on the formulation of inactivated antigen with
conventional adjuvants such as oil-in-water emulsions.5 In
countries free of FMD, besides culling infected herds, vaccines
can have an important role in the control of outbreaks.
Nevertheless, the ability to induce early protection is an essential
element of such vaccines. A problem associated with the
elimination of FMD from endemic areas is the fact that current
vaccines offer protection with a very limited duration of
immunity.6 A potential to improve such vaccines would be to
enhance their ability to activate the innate immune system by
targeting Toll-like receptors (TLRs), which can promote T-cell help
and differentiation of B lymphocytes into memory or long-lived
plasma cells.7 TLR are a family of pathogen recognition receptors
(PRR) typically expressed at high levels on specialized antigen-
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presenting cells and are central for alerting the innate immune
system in case of infection. Cell surface TLRs, such as TLR4,
recognize microbial pattern molecules such as bacterial lipopoly-
saccharides, whereas endosomal TLRs such as TLR7 and
TLR9 sense single-stranded RNA or microbial unmethylated DNA
with many CpG motifs, respectively. In fact, TLR4 and TLR7 ligands
were shown to strongly enhance antibody responses in the mouse
model,7 and were therefore selected for the present study.
Based on this, one aim of this work was to determine the
potential of such TLR ligands to improve the immunogenicity of
an inactivated vaccine in large animals using an FMD vaccine as a
model. We used sheep as a model for an ungulate that is naturally
susceptible to FMD virus (FMDV). Although in western countries
small ruminants usually are not considered in vaccination
program, the immune system of sheep and cattle are relatively
similar and the use of sheep requires less space and ﬁnancial
resources. Furthermore, in certain areas of the world small
ruminant represent the main FMD-susceptible livestock and can
play an important role for spreading the infection during
outbreaks.8–10
Our second important aim was to transfer human BTMs to the
sheep model and identify gene sets correlating with antibody
levels as well as vaccine side effects. We also successfully
employed this bioinformatics pipeline to characterize vaccine-
adjuvant-dependent modulation of the immune responses as well
as the pre-vaccination transcriptome associated with high
immune responses.
RESULTS
Antibody responses
Three groups of sheep were vaccinated with FMDV antigen
formulated either in buffer (PBS), in liposomes (L) or in liposomes
containing TLR4 and TLR7 ligands (L(TLRL)), and the ability of the
vaccines to induce an early neutralizing antibody response was
tested (Fig. 1a). For the physicochemical characterization of the
vaccines see Supplementary Fig. 1. Although animals from all
groups responded to vaccination, at day 7 p.v. (D7) only the serum
neutralization titers (SNTs) of those receiving liposomal formula-
tions raised above 1:20, which is generally considered to be
associated with protection.6 Over the time observed, most animals
stayed above this critical titer in the L(TLRL) group. Nevertheless,
due to the high variation in the response of individual animals,
statistically signiﬁcant differences were only found when the L
(TLRL) was compared with the PBS group (Fig. 1a).
Vaccine-induced haptoglobin and transcriptional modulations
As liposomal formulations caused lameness in some animals for
1–2 days after injection, we also quantiﬁed systemic inﬂammation
by measuring serum haptoglobin, an acute-phase protein induced
in the liver by pro-inﬂammatory cytokines,11 and which represents
a sensitive marker of inﬂammation following sheep vaccination.12
Our results demonstrate that liposomal formulations were indeed
associated with an acute-phase response peaking at D3 and still
detectable in most animals at D7 (Fig. 1b). Interestingly, the TLRL
did not enhanced but actually reduced this response (p= 0.013
for L versus L(TLRL) at D3).
Also at the transcriptional level, the liposomal formulations
caused a stronger perturbation of the immune system, but this
was dampened by the addition of TLRL (Fig. 1c). For example,
when comparing and peripheral blood mononuclear cells (PBMCs)
before and at D3 (D0 vs. D3), PBS induced the signiﬁcant
upregulation of 116 genes, L of 216 genes, and L(TLRL) only of 7
genes. Nevertheless, at D7, the TLRL-adjuvant group had clearly
the most up- or downregulated transcripts (Fig. 1c and
Supplementary Fig. 2). We found 53 common genes between
the L and L(TLRL) groups, and 63 common genes for the L and PBS
groups (Supplementary Fig. 2) but no common genes for all three
formulations.
Individual transcripts correlating with neutralizing antibody titers
Individual changes in gene expression were calculated and
correlated with the SNT on day 7, 14, and 28 p.v. (Supplementary
Fig. 3). For the D0 vs. D3 differentially expressed genes, 26
transcripts (ZNF646, STIM2, C9orf3, NPEPPS, SDR39U1, HEXDC,
NUCB2, GHDC, LSR, MYO1E, TRAPPC6A, DCAF12, ABCC2,
ZDHHC24, TRIM41, GZMA, NAGK, GMNN, OLFML3, MYO7A,
TNFSF13B, GGA3, ASB8, ARNTL, GNG3, PLA2G12A) were identiﬁed
to correlate with the SNT of all three time points (7, 14, and
28 days). For the D0 vs. D7 differentially expressed genes, six
transcripts were found to correlate with SNT of all three time
points (CHPT1, RPL12, RNASEL, CCDC93, MFAP2, MYO1E). Only
MYO1E was correlating at D3 as well as D7 with the SNT at all time
points.
Translation of human BTM to the sheep
While some of the genes identiﬁed above are clearly linked to
antibody responses such as TNFSF13B (B-cell-activating factor),
the potential involvement of most genes in promoting antibody
responses remained elusive. We therefore employed gene set
enrichment (GSEA) using BTM developed in the human system.
These have been demonstrated to provide a comprehensive
picture of human immune responses correlating with adaptive
immune responses induced by different classes of vaccines.1
Figure 2a shows the number of genes in the human and
corresponding sheep modules, and Fig. 2b the coverage of the
BTM using annotated sheep genes. The list of all BTM with their
gene compositions can be downloaded from the Supplementary
Data. At the time of writing this manuscript, the incomplete
annotation of the sheep genome enabled an overall 76.79%
coverage of the BTM (mean value).
BTM correlating with antibody responses
The correlation of BTM with antibody responses measured at 7, 14,
and 21 days p.v. were determined for the D3 and D7
transcriptome (Fig. 3a,b, respectively). Although some BTM
correlated only with one of the time points p.v., other correlated
with two or all of the time points analyzed. This was expected as
some animals with low early antibody levels caught up at day 28
p.v. (Fig. 1a). Nevertheless, for D3 the BTM M209 (lysosome) and
M23 (RA, WNT, CSF receptor network) positively correlated with
the SNT at all time points. Furthermore, despite the variation in
antibody responses over time, a number of BTM were found that
negatively correlated to antibody responses measured at all three
time points. These were mainly BTM related to cell proliferation
(M4.10, M37.3, M10.0) and T/natural killer (NK) cells (M7.2, M61.2,
M35.1, M7.3).
Antibody-correlating D7 BTM were reduced in numbers (Fig.
3b). Nevertheless, some BTM were found again, such as M146
(MHC-TLR7-TLR8 cluster, positive correlation), M35.1 (signaling in
T cells, negative correlation), and M250 (spliceosome, negative
correlation).
To enable an easier interpretation of the BTM results, we
classiﬁed them into six BTM families (Table 1 and Supplementary
Excel ﬁle “BTM composition and families”). To this end, BTM were
attributed to immune cell types or immunological processes, for
which we decided to make large families to obtain a simpliﬁed
synopsis of early immune responses correlating to antibody titers.
As an example, the BTM family “myeloid cells/inﬂammation” was
composed of all BTM’s relating to monocytic cells, neutrophils, and
other elements of inﬂammatory reactions. We also included BTM
related to coagulation and complement activation, as these are
processes induced during inﬂammation (Table 1). The result of
System immunology-based identiﬁcation of blood transcriptional
RO Braun et al.
2
npj Vaccines (2018)  41 Published in partnership with the Sealy Center for Vaccine Development
1
2
3
4
5
6
7
8
9
0
()
:,;
Fig. 1 Neutralizing antibodies, haptoglobin and differentially expressed genes in PBMC induced by vaccination. a Serum neutralizing
antibody titers following vaccination of sheep with antigen in phosphate buffered saline (PBS), antigen formulated in liposomes (L) and
antigen formulated in liposomes with TLRL (L(TLRL)). The dotted line represents the titer predicted to be protective. b Vaccine-induced
haptoglobin responses. c Vulcano plots showing differentially expressed genes which were up- or downregulation on day 3 (D3) and day 7
(D7) compared with before immunization, respectively. Green dots represent signiﬁcant genes (p < 0.01). Digits in the plots indicate the
number of signiﬁcantly down or upregulated genes. In a and b, statistical signiﬁcant differences between two groups were calculated using
unpaired two-way ANOVA followed by Tukey’s multiple comparisons test (***p < 0.001; **p < 0.002; *p < 0.033)
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such an analysis for the correlating BTM is shown in Fig. 4a and
demonstrate that the D3 dominant BTM families positively
correlating with antibody responses were “myeloid cells/inﬂam-
mation” and “DC/antigen presentation,” whereas the BTM families
“T/NK cells” and “cell cycle” were the most prominent to
negatively correlate. This dominance was seen in terms of the
number of correlating BTM’s attributed to the family for each of
the analyses. The polar plots created for day 7 did not enable the
identiﬁcation of clearly dominant BTM families because of the
reduced number of correlating BTMs. Interestingly, at this later
a Correlating BTM D0 vs D3 b Correlating BTM D0 vs D7
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endoplasmic reticulum (M37.2)
E2F1 targets (Q4) (M10.1)
E2F1 targets (Q3) (M10.0)
DNA repair (M76)
cytokines − recepters cluster (M115)
complement and other receptors in DCs (M40)
complement activation (II) (M112.1)
complement activation (I) (M112.0)
chemokines and receptors (M38)
cell division stimulated CD4+ T cells (M46)
cell division in stimulated CD4 T cells (M4.6)
cell division (M37.3)
cell division − E2F transcription network (M4.8)
cell cycle, mitotic phase (M230)
cell cycle (III) (M103)
cell cycle (II) (M4.10)
cell cycle (I) (M4.1)
CD4 T cell surface signature Th1−stimulated (S6)
blood coagulation (M11.1)
antigen processing and presentation (M200)
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Fig. 2 Translation of human blood transcriptional modules to the ovine system. a Number of human and sheep genes assigned to 349 BTM
(based on annotation of the sheep genome at the time of analyses). b Coverage of sheep genes assigned to BTM compared with the original
composition.1
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time point the BTM family “myeloid cells/inﬂammation” was
negatively correlating with antibody levels.
Vaccine-induced BTM’s
We next calculated BTM’s signiﬁcantly induced by the different
vaccines with the aim to compare these responses with the
antibody-correlating BTM, and to determine the effects of
formulation and TLRL. The results are shown as BTM families in
Fig. 4b and as heatmap for individual BTM in Supplementary Fig.
4. On D3, both liposomal formulations strongly promoted
“myeloid cells/inﬂammation” and “DC/antigen presentation” but
downregulated “T/NK cells” and “cell cycle” BTM families. The
addition of the TLRL reduced “myeloid cells/inﬂammation” and
“DC/antigen presentation” BTM. The PBS group had a milder effect
Fig. 3 BTM correlating to serum neutralizing antibody titers. a Heatmap showing the correlation of D3 BTM with antibody levels on day 7, 14,
or 28 after immunization. Animals from all groups were included (n= 18, cutoff p < 0.05). b Heatmap showing the correlation of D7 BTM with
antibody levels in analogy to a
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on upregulated BTM families and, more interesting, an opposing
effect on the “T/NK cells” and “cell cycle” families. Interestingly, at
D3 and D7 the “B-cell” family was dominantly upregulated only in
the TLRL group. This could be relevant with respect to the ability
of TLRL to enhance antibody responses, since “B cells” BTM were
found to positively correlate with antibody responses (Fig. 4a). In
all vaccine groups, an opposing modulation was found for
“myeloid cells/inﬂammation,” “DC/antigen presentation,” and “cell
cycle” BTM families, when D7 was compared with D3.
Inverse correlation of BTM to the acute-phase response compared
with that of antibody responses
To differentiate innate immune responses associated with anti-
body responses or unwanted inﬂammation, we calculated the
correlation of BTM with the haptoglobin responses (Fig. 5 and
Supplementary Fig. 5). At D3, negative correlations were found for
the “myeloid cells/inﬂammation” and “DC/antigen presentation”
but positive correlation for the “T/NK cells” and “cell cycle” BTM
families. As this represents a reverse correlation compared with
that found for the antibody levels, we conclude that acute-phase
reactions likely indicate unwanted inﬂammatory side effects.
Nevertheless, this conclusion was not possible for D7, when most
BTM showed a negative correlation.
Pre-vaccination BTM associated with antibody levels
Considering the heterogeneity of vaccine-induced antibody
responses (Fig. 1a), we tested is certain BTM would be associated
with higher levels of antibody response. To this end, in each
vaccine group animals having an SNT at day 28 of > 50% above
the median were deﬁned as “high responders” (n= 6) and those
with < 50% of the median as “low responders” (n= 6). A
comparison of high and low responders using GSEA demonstrated
that 16 BTM related to cell cycle and DNA repair, seven BTM
related to myeloid cells, six BTM related to DC, and six BTM related
to inﬂammation and innate immune responses were expressed at
relatively higher levels in the “high responders” (Fig. 6a). Only a
total of ﬁve BTM were higher in the “low responder” animals,
which included BTM related to interferon (IFN) type-I and B-cell
responses. Figure 6b shows a heatmap for the BTM “monocyte
surface signature (S4) as an example of this analyses.
DISCUSSION
The present study adapted BTM originally developed for human
blood to sheep PBMC to understand vaccine-induced responses
correlating with antibody and acute-phase responses. For efﬁcient
delivery to antigen-presenting cells, we employed synthetic
liposomes as vaccine platform and tested the effect of a
combination of TLR4 and TLR7 ligands on antibody and acute-
phase protein response. These ligands were selected based on
their synergistic potentiation of antibody responses in a mouse
model.7 Speciﬁcally, the TLR7 ligand Gardiquimod was selected
based on its ability to induce proliferation and induce IFN-α in
PBMC,13,14 and the TLR4 ligand monophosphoryl lipid A (MPLA)
based on its potent triggering of nuclear factor-κB signaling,
which promotes pro-inﬂammatory responses in mononuclear
phagocytes.15,16 Furthermore, MPLA is clinically approved and
was also recently reported to induce a similar response in sheep
compared with human PBMC.17 The vaccination of sheep was
successful in terms of induction of neutralizing antibody titers
above a titer of 1:20, which has been proposed as a critical
threshold for protective immunity.6 Also, the addition of the TLRL
signiﬁcantly enhanced the number of animals reaching titers
above this threshold. Nevertheless, due to high variability
between the animals, no statistically signiﬁcant differences in
the antibody titers where found when comparing the L with the L
(TLRL) groups. Nevertheless, it is clear that the present vaccine still
requires signiﬁcant improvements, and thus future studies
focussing on the effects of formulation, TLR ligand selection and
dose in sheep are needed.
Interestingly, although the increase in antibody responses
induced by the TLRL was disappointing, it had a clear effect on
the expression of individual genes. Strikingly, the overall
perturbation of gene expression was reduced at D3 in terms of
differentially up- or downregulated genes when compared with
the L group. Furthermore, on day three p.v., the PBS group shared
many upregulated genes with the L, but not with the L(TLRL)
group. At day 7, this was even more evident in that differentially
regulated genes were found almost exclusively in the TLRL-
adjuvanted group. Also, comparing the vaccine groups using BTM
conﬁrmed clear effects of the TLRL. The reduction of upregulated
“myeloid cells/inﬂammation” and DC/antigen presentation” BTM
at D3 together with the above reduced perturbation of individual
Table 1. Deﬁnition and composition of BTM families
BTM families Immune cells and processes BTM included
Myeloid cells/
inﬂammation
Myeloid cells, innate/inﬂammatory response (inﬂammatory
cytokines and chemokines), leukocyte migration, coagulation and
platelet activation, complement activation
M0, M4.3, M4.15, M11.0, M11.1, M11.2, M16, M21, M23,
M24, M27.0, M27.1, M29, M33, M37.1, M38, M39, M45,
M53, M59, M73, M78, M81, M85, M86.0, M86.1, M88.0,
M91, M112.0, M112.1, M115, M118.0, M118.1, M132, M163,
M199, S4, M30, M32.0, M32.1, M37.0, M42
DC/antigen
presentation
DC surface (resting and activated), antigen processing and
presentation, DC activation
M5.0, M25, M28, M40, M43.0, M43.1, M50, M64, M67, M71,
M87, M95.0, M95.1, M119, M138, M139, M146, M165,
M168, M200, M209, S5, S10, S11
T/NK cells NK and T-cell surface, differentiation, activation, signaling, co-
stimulation, and proliferation
M4.5, M4.6, M4.9, M4.11, M5.1, M7.0, M7.1, M7.2, M7.3,
M7.4, M12, M14, M18, M19, M35.0, M35.1, M36, M44, M46,
M52, M61.0, M61.1, M61.2, M65, M126, M157, M223, S0,
S1, S6, S7
B cells B cells, BCR signaling, B-cell development and differentiation,
plasma cells, immunoglobulins
M9, M47.0, M47.1, M47.2, M47.3, M47.4, M58, M69, M83,
M123, M156.0, M156.1, M217, S2, S3, S8, S9, M152.0,
M152.1, M152.2, M182
Cell cycle Cell cycle, proliferation, DNA repair, nucleotide and amino acid
metabolism, splicing
M76, M103, M4.10, M4.12, M4.0, M4.1, M4.2, M4.4, M4.7,
M4.8, M6, M8, M10.0, M10.1, M20, M22.0, M22.1, M31,
M32.2, M32.4, M37.3, M49, M144, M167, M175, M181,
M230, M250, M15, M143, M154.0, M169
IFN type-I Nucleic acid sensing, IFN type-I induction, and IFN response
signature
M13, M68, M75, M111.0, M111.1, M127, M150, M158.0,
M158.1
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genes and the reduced induction of haptoglobin indicates an anti-
inﬂammatory effect of the TLRL. Future studies are required to
understand how this is induced and if it is an effect of one of the
TLRL or their combinations. The fact that at D7 the L(TLRL) group
showed the strongest perturbations, both at the individual gene
and BTM level, demonstrates that this is not a simple suppressive
effect but that rather long-lasting immunomodulatory circuits are
induced.
The analysis of genes correlating positively or negatively with
antibody titers revealed a relatively large number of genes. We
focused mainly on those found to correlate at least for two
different time points to increase the chance to have truly relevant
genes. Nevertheless, for most of the correlating genes, their role in
immune responses is unclear, with the exception of TNFSF13B
representing BAFF. Furthermore, only few of the correlating genes
matched those identiﬁed in PBMC from humans vaccinated with
Fig. 4 BTM families correlating with antibody responses and induced by the vaccines. BTM families were created as described in Table 1. a The
polar plots show the correlation coefﬁcients for BTM of the module families with signiﬁcant positive or negative correlation to neutralizing
antibody levels in serum (p < 0.05). BTM for the D3 (upper plots) and D7 (lower plots) transcriptome are shown. b Vaccine-dependent BTM
modulations were calculated as normalized enrichment scores (NES) using GSEA. The signiﬁcantly (p < 0.05) modulated BTM were grouped as
BTM families as in a. The data are shown was calculated for each vaccine group with the D3 (upper plots) and D7 (lower plots) transcriptome
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an inactivated viral vaccine.2 For these reasons, we employed the
BTM as a much more powerful bioinformatics analysis of
transcriptomic data. BTM represent master networks of immuno-
logical genes strongly co-regulated and interacting during many
physiological and pathological conditions.1 This approach per-
mitted to identify many BTM expressed on D3 and D7 correlating
with antibody responses on day 7, 14, and 28 p.v. Remarkably,
many of the correlating BTMs were also found in human
vaccination studies using protein-based or inactivated vaccines.
Prominent amongst these are positively correlating BTM relating
to monocytes such as M11.0, M23, and M118,1,18–20 to
complement activation such as M112,1,20 to TLR/antigen pre-
sentation such as M146 and M251,18,20, and to B cells and plasma
cells such as M47, M156, and S3.18 Among prominent negatively
correlating modules appearing in both human and sheep
vaccination studies are the NK cell signature BTM M61.1, M61.2,
and M61.318,20,21, and less frequent M250 “spliceosome”.1 In
sheep, many T-cell modules including CD4 T-cell BTM (M4.X) and
general T-cell activation modules (M7.X) were negatively corre-
lated with antibodies. Nevertheless, the various reports on human
studies indicate that this can strongly vary depending on the time
point being analyzed, the vaccine employed, the number of
vaccinations, and the age,1,20,21 although M7.1 and M7.2 were
often negatively correlated with antibody response salso in
human studies.1,18,20,21 For the cell cycle modules which were
also among the BTM with a negative correlation in sheep, this was
rarely found in the human studies using protein-based vaccines,
indicating possible species differences or alternatively a speciﬁc
effect of the liposomal vaccine employed in the present study.
Clearly, the correlating BTM response strongly depends on the
type of vaccine.1 Altogether, we propose that the common
correlating BTM found for several different inactivated/protein-
based vaccines in both species could be particular robust
measurements. From our data, we also conclude that measuring
the transcriptome early after vaccines provides more correlating
BTM and, therefore, more information regarding the effects of the
vaccine on the immune system.
For the immunological interpretation of these results, it must be
considered that blood represents only a transit compartment for
immune cells. As a result of vaccine-induced innate immune
responses, haematopoiesis of myeloid cells and DC is likely to be
enhanced explaining the increase of many modules relating to
these cell types. Furthermore, it is obvious that despite the
intramuscular injection, the vaccines cause systemic inﬂammatory
effects, some of which obviously correlate with antibody
responses. These are not only a number of modules relating the
DC and antigen presentation but also to complement activation
and blood coagulation. With these reactions, it is also possible to
explain the negative correlation of T/NK cell modules, as these
cells are very quickly recruited to lymphoid tissues following acute
innate immune response such as virus infections.22 The negative
correlation of cell cycle BTM could be related to the same
mechanisms as T cell represent the main cell fraction in PBMCs
Fig. 5 BTM families correlating to vaccine-induced haptoglobin levels. BTM families were created as described in Table 1. The polar plots show
correlation coefﬁcients for module families with signiﬁcant (p < 0.05) positive or negative correlation to serum haptoglobin levels. BTM families
for the D3 (upper plots) and D7 (lower plots) transcriptome are shown
Fig. 6 Pre-vaccination BTM associated with antibody levels. a GSEA
was used to determine the BTM enriched in “high responders” (n=
6, red) and “low responders” (n= 6, blue). The colors indicates the
NES. b Heatmap for the BTM “monocyte surface signature” (S4) as an
example of the analysis in a. Each square represents the indicated
gene expression for individual animals (same color code as in a)
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and many such BTMs were actually related to T cells, in particular
CD4 T cells.
An important question arising from such studies is whether the
above BTM represent mechanistically relevant modules or, on the
contrary, modules that also reﬂect unwanted side effects of strong
adjuvants. To address this question, we performed two additional
analyses, which were to compare the correlating BTM with the
vaccine-induced BTM, as well as to identify BTM correlating with
an acute-phase protein. Although the overall pattern of BTM
modulation was similar for the liposomal formulations on D3, the
BTM correlating to the haptoglobin levels were opposite. In fact,
the liposomal vaccines induced an upregulation of “myeloid cells/
inﬂammation,” “DC/antigen presentation,” “B cells” BTM, and a
downregulation of “T/NK cells” and “cell cycle” BTM, whereas the
correlation of these BTM families to the haptoglobin response was
inverse. This suggests that the way the vaccine modulates these
BTM early after injection would be rather beneﬁcial to the immune
response and not directly linked to vaccine side effects. We also
performed a correlation analysis of haptoglobin and antibody
responses, and found neither evidence for a positive nor for a
negative correlation. Nevertheless, at D7 many of the induced
BTM were now relatively downregulated and this change was only
partially recapitulated by the D7 BTM correlating to the antibody
levels. It could therefore be speculated that some of these long-
lasting perturbations of the immune system could be related to
unwanted inﬂammation rather than vaccine potency. More
studies with different kinds of adjuvants will shed light on this
question.
The main difference with the PBS group was that it did not
impact the “T/NK cell” BTM and had an opposite effect
(upregulation) on the “cell cycle” BTM. We speculate that in the
absence of liposomal formulation the inﬂammatory responses and
the presence of antigen-loaded activated DC in draining lymph
nodes could be reduced explaining a reduced recruitment of
these cells to lymphoid tissue.
Finally, we also tested whether different pre-vaccination
expression levels of BTM can be identiﬁed in low or high
antibody-producing sheep. Our data indicate that this is possible
even with relatively small group sizes. The relative upregulation of
cell cycle, monocyte, DC and innate/inﬂammatory response BTM
in the “high responders” would indicate that the immune system
of those animals is in a kind of pre-activated status. Nevertheless,
this status was different from that induced by the TLR-adjuvanted
vaccines which induced an opposite regulation of cell cycle, T/NK
cells, and B-cell BTM. A possible explanation for the combination
of increased levels of myeloid cell/DC and cell cycle BTM could be
increased hematopoiesis and egress of cells from the bone
marrow and thymus. Future studies could aim at inducing such a
status to enhance vaccine-induced responses.
Obviously, there many other possibilities to analyze gene sets
and a choice from a multitude of possible gene sets, including
pathways and molecular network-based gene sets,23,24 must be
made. An example for a different approach selected in cattle is the
study by Laughlin et al.25 using established canonical pathways
and gene ontology networks analyzed using a method called
Dynamic Bayesian Gene Group Activation. Although many of the
gene sets identiﬁed to correlate are related to those found using
the BTM method, a direct comparison is difﬁcult. To enable a
comparison of our data with a relatively large set of human
vaccination data, we selected the BTM method for the present
study.
In conclusion, the present work has developed a system
immunology readout in the ovine model composed of many
immunologically relevant gene expression networks, which
correlate with antibody responses. We anticipate that this is
applicable to other species and will be very useful to both the
identiﬁcation of efﬁcient vaccine adjuvants causing little
unwanted side effects and to ﬁnd factors related to low vaccine
responders.
METHODS
Vaccine preparation
The TLR4 ligand MPLA was from Avanti Polar Lipids (USA) and the TLR7
ligand guardiquimod from Chemdea (USA). DPPC, DCChol, and PHAD were
purchased from Avanti Polar Lipids; Hepes from Applichem; sucrose,
chloroform, and ethanol from Sigma-Aldrich (Switzerland). Extruder
membranes of 400 and 200 nm pore size, as well as draining disks, were
purchased from VWR International (Switzerland). Small-scale liposome
formulations for evaluation were prepared as follows. DPPC and DCChol
stocks were prepared at 50mg/ml in methanol/methylen-chloride 1:1
(Sigma-Aldrich). Sixteen milligrams of total lipid mix was prepared and
evaporated in an Eppendorf Vacufuge. Lipids were resuspended in 1ml
20mM HEPES, 10% sucrose buffer on a shaker for 60min. Liposomes were
serially extruded using an Avanti Mini Extruder (Avanti, USA) with 400, 200,
and 100 nm membranes (Avanti). For each ﬁltration step, liposomal
solutions were passed 11 times. Large-scale liposomal formulation for the
in vivo vaccine trial were made as follows. A solution of DPPC (2.6 mL) at
30mg/mL in chloroform (78.5 mg) and 1.9 mL of a solution of DCChol at
30mg/mL in chloroform (57.3 mg) were mixed in a 50ml round-bottom
ﬂask. The solvent was evaporated with rotary evaporator (Laborota 4001,
Heidolph) at 40 °C. The lipid ﬁlm was rehydrated with 8.5 ml of pre-warmed
(40 °C) 20mM Hepes buffer containing 10% sucrose, pH 7.4, to obtain a
lipid concentration (DPPC+ DCChol) of 16 mg/ml, a DPPC concentration of
9.2 mg/ml, and DCChol concentration of 6.7 mg/ml. The mixture was
magnetically stirred for 25min and incubated for 5 min at room
temperature (RT). The mixture was inserted into an extruder (T.001,
Northern Lipids, Inc.) equipped with a thermo barrel of 10 ml and
equilibrated at 50 °C. After ﬁve extrusion cycles with a ﬁlter of pore size of
400 nm and ﬁve cycles with a ﬁlter of 200 nm, the liposome suspension
was ﬁltered through a 0.22 µm ﬁlter to recover 7.5 ml of the sterile product.
The ﬁltered product was ﬂushed with a nitrogen stream and stored at 4 °C.
Cationic liposomes containing gardiquimod were prepared with the
same procedure by rehydrating the lipid ﬁlm with 8.5 ml of pre-warmed
(40 °C) 20mM Hepes buffer containing 10% sucrose and gardiquimod at
1mg/ml, ﬁnal pH 7.4. Cationic liposomes containing MPLA were prepared
with the same procedure, except that 1.7 ml of a solution of MPLA in
chloroform at 1mg/ml was added to the chloroform solutions of DPPC and
DCChol before evaporation and formation of the lipid ﬁlm. Liposomes
were formulated with antigen to ﬁnal concentration of 8 mg/ml lipid and
20 μg/ml FMDV 146S antigen (FMDV A Iran96, kindly provided by Merial
Ltd, Pirbright, UK) using a HEPES/Sucrose buffer under stirring.
Vaccine characterization
The liposome products were characterized immediately after preparation
by measuring pH, average particle size, polydispersion, zeta potential (light
scattering, Zetasizer Nano ZS, Malvern), and lipid component concentra-
tion (RP-HPLC, Agilent). In addition, liposomes were assessed by
transmission electron microscopy after negative staining. A droplet of
the liposome suspension diluted 1:5 in buffer was placed on a collodion/
carbon-coated 300-mesh copper grid (Electron Microscopy Sciences,
Hatﬁeld, PA). After waiting 1min to permit adsorption, excess liquid was
blotted with a ﬁlter paper and a drop of 2% phosphotungstic acid at pH 7.0
was added. After another 45 s, the negative stain was removed by
touching a ﬁlter paper to the edge of the grid. Samples were dried
overnight at RT and examined with a Philips CM12 transmission electron
microscope (FEI, The Netherlands) at an accelerating voltage of 80 kV with
primary magniﬁcations ranging from × 25,000 to × 110,000. Micrographs
were captured with a Mega View III camera using the iTEM software
version 5.2 (Olympus Soft Imaging Solutions GmbH, Münster, Germany).
For the data see Supplementary Fig. 1.
Immunization of sheep
Three groups of six Skudden sheep were immunized intramuscular with
2ml vaccine dose containing 146S antigen in PBS (PBS), antigen
formulated in liposomes (L), or antigen formulated in liposomes together
with MPLA/Gardiquimod as TLR ligands (L(TLRL)). A power calculation to
determine the number of animals was performed. We assumed to ﬁnd an
increase of antibodies by 90% with a power of 1-β= 0.8 (80% security) a
group size of six would be enough, estimating a SE of lower than 40%. An
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error ɑ of 0.05 and an error β of 0.2 was employed. Each group was
composed of three young (5–6 month of age) and three older (1–2 years of
age). Serum and PBMC samples were taken previous to vaccination and on
day 3, 14, and 28. The animal experiment was performed in accordance to
the Article 18 of the Swiss Animal Welfare Act (TSchG) and was approved
by the Cantonal Ethical Committee for animal experiments.
Serum neutralization assay
Clot activator tubes (Becton Dickinson) were used to sample serum, which
was centrifuged at 1000 × g and stored at − 20 °C until analysis. Serum was
heat-inactivated at 56 °C for 30min. Twofold serial dilutions of serum
starting with 1:10 were performed in 50 μl ﬁnal volume. Fifty microliters of
FMDV A Iran96 at 100 TCID50 was added to each well and incubated at
37 °C 5% CO2 for 1 h. Samples of vaccinated cattle were used for
standardization purpose. LFBK-αVβ6 cells26 (kindly obtained from Dr. Luis
Rodriguez, Plum Island Animal Disease Center, New York, USA) were added
to wells in suspension (100 μl at 2 × 105 cells/ml) and incubated for 72 h.
Cytopathic effect was used for readout. The Reed and Muench formula was
used for calculation of neutralizing titer.27 Statistical analyses for
differences in antibody responses used two-way analysis of variance
(ANOVA) combined with Tukey’s multiple comparison test.
Haptoglobin
Serum haptoglobin was measured using a the Tridelta PHASE haptoglobin
assay (Tridelta Development Ltd, Ireland). Statistical analyses for differ-
ences in haptoglobin responses used two-way ANOVA combined with
Tukey’s multiple comparison test.
Isolation of PBMC RNA
Blood was collected in EDTA-coated tubes (Becton Dickinson) and PBMCs
were isolated by density centrifugation (1000 × g, 25 min) over Ficoll-Paque
(GE Healthcare, UK) using citrated blood. Five million PBMCs were
centrifuged at 350 × g and the pellet was resuspended in 1 ml TRIzol(R)
(Thermo Fisher). RNA was isolated using the NucleoSpin RNA kit
(Macherey-Nagel, Germany). Chloroform:IAA (0.2 ml; 49:1) was added per
ml of TRIzol and tubes were shaken vigorously for 15 s followed by
incubation for 3 min at RT. Then, the tubes were centrifuged at 12,000 × g,
4 °C for 15min and the aqueous phase was transferred to new tubes and
mixed with 500 μl isopropanol. After incubation for 10min at RT, the
samples were loaded on to NucleoSpin RNA columns and centrifuged at
11,000 × g for 30 s. MDB (350 μl) was added to columns followed by
centrifugation at 11,000 × g for 30 s. DNase mixture (95 μl) was applied on
the membranes for 20min followed by washing with RAW2 buffer and
centrifugation as above. This was repeated twice with 600 μl and 250 μl
RA3 buffer, respectively. RNA was eluted with 40 μl RNase-free water and
centrifugation at 11,000 × g for 1 min. Samples were stored at − 70 °C until
analysis.
RNA-seq data analysis
Between 2.9 and 22.5 million read pairs were obtained per sample and the
quality of the reads was assessed using fastqc v.0.11.2 (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/). Ribosomal RNA (rRNA)
was removed by mapping the reads to a collection of rRNA sequences
(ensembl release 3.1) with Bowtie2 v. 2.2.1.28 The remaining reads were
mapped to the Ovis aries reference genome (Oar_v3.1) with Tophat
v.2.0.13.29 We used htseq-count v.0.6.130 to count the number of reads
overlapping with each gene, as speciﬁed in the ensembl annotation
(Oar_v3.1.86). The Bioconductor package DESeq2 v. 1.10.131 was used to
test for differential gene expression between the different time points and
vaccines. Detailed information about the genes including the Entrez Gene
ID, the description of the gene, the human homolog ensembl gene ID and
the human homolog gene name was obtained using the Bioconductor
package BioMart v. 2.26.1.32
BTM analyses
To further analyze the molecular signatures of the response to different
vaccines, we performed a GSEA using blood transcription modules deﬁned
by Li et. al.1 These modules are composed of 9 up to 347 different genes.
The GSEA tool (software.broadinsititute.org)33 was used to calculate
enrichment scores for BTMs with each individual animal. Pearson’s
correlation of enrichment scores with antibody or haptoglobin levels
was calculated in R. GSEA was also used to compare to compare the
different vaccines. To this end, a grouped GSEA was performed. To analyze
difference in high and low antibody responders, animals in each vaccine
group having an SNT at day 28 of > 50% above the median were deﬁned
as “high responders” (n= 6) and those with < 50% of the median as “low
responders” (n= 6). Two animals per vaccine group ﬁtted into each these
criteria. Then GSEA was used to compare BTM levels found in high and low
responders. Heatmaps, scatter plots, and polar plots were created using
the ggplot 2 package or Graphpad Prism 7.0.
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